The Efficacy and Safety of Regorafenib in Combination With Anti-PD-1 Antibody in Refractory Microsatellite Stable Metastatic Colorectal Cancer: A Retrospective Study

BACKGROUND: Microsatellite stable (MSS) or mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC) is resistant to immune checkpoint inhibitors. However, a recent Japanese trial showed that regorafenib plus nivolumab had encouraging anti-cancer activity in MSS or pMMR mCRCs. MATERIALS...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jisheng, Cong, Lei, Liu, Jintao, Peng, Ling, Wang, Jun, Feng, Alei, Yue, Jinbo, Li, Li, Wang, Xiuwen, Wang, Xiangling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7689210/
https://www.ncbi.nlm.nih.gov/pubmed/33282742
http://dx.doi.org/10.3389/fonc.2020.594125

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7689210/
https://www.ncbi.nlm.nih.gov/pubmed/33282742
http://dx.doi.org/10.3389/fonc.2020.594125

Ejemplares similares